• gmp-verlag.de
  • GMP MANUAL Login
  • Shopping cart
Stay informed!

You’d like to be regularly informed on the latest developments in Good Manufacturing Practices?

 

Subscribe to our free GMP Newsletter LOGFILE!

>>> REGISTER NOW

The New USP <1231>
Water for Pharmaceutical Purposes

a detailed Overview

>>> ORDER NOW

Award for the
GMP Compliance Adviser

GMP knowledge that convinces.

Image

On 7 June 2016 Maas & Peither GMP Publishing has received a

SIPAward in the category
"Best New Success Story" and was awarded with the 3rd place.

The GMP MANUAL (now: GMP Compliance Adviser) impressed the jury with "Safe Drugs through Better GMP Understanding".


GMP Compliance Adviser

GMP in Practice: 24 chapters written by internationally renowned industry experts.

 

GMP Regulations: 8 chapters with the most important GMP guidelines and regulations.

 

Image

>>> READ MORE

TOP 5 GMP Downloads

1. Questionnaire for preparing GMP-inspections
More than 650 typical questions related to audits and inspections.


2. GDP Audit Checklist
More than 700 questions with reference to regulations.


3. GMP Fundamentals
A quick and comprehensive overview of the complex world of GMP.


4. Industry Guide to handle OOX Test Results
Every single step of the OOX process.


5. The New USP <1231>: Water for Pharmaceutical Purposes
A compact overview of the contents of the new version of USP <1231>.


>>> More Downloads

News about GMP/cGMP

2018-01-15

Swissmedic updates Biosimilar Guidance and FAQs

Swissmedic has announced that as of now, the foreign comparator product with a biosimilar for the main studies can also originate from the USA, while that for supplementary studies can now also originate from Canada.

 

8.3.1 “If a comparator product from a foreign country (EU, USA, Japan or Canada) is used, the equivalence of the foreign comparator product with the Swiss reference product must be demonstrated in order to prove that the investigation results can be transferred to the reference product.

For main studies on the comprehensive comparability with the biosimilar, Swissmedic to date has only accepted the reference product from Switzerland or a product from the EU. For supplementary studies, comparator products from Japan have also been accepted.

Another new aspect to consider ist that as of now an Environmental Risk Assessment (ERA) is compulsatory for biosimilar submission to Swissmedic.

8.1.1 “When applying for authorisation of biosimilars, an Environmental Risk Assessment (ERA) must be submitted or else an appropriate reason given for not submitting one”.

The guidance document “Authorisation of Biosimilars” as well as the corresponding Q&As have been updated accordingly.

Source:

Swissmedic: News & Updates

Comments
No comment has yet been written about this news.